Scarica l'app Stockscreener
5.01
6.88%
-0.37
Dopo l'orario di chiusura:
4.85
-0.16
-3.19%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Pluri Inc Borsa (PLUR) Ultime notizie
Pluri First Quarter 2025 Earnings: US$1.08 loss per share (vs US$0.96 loss in 1Q 2024) - Yahoo Finance
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - StreetInsider.com
BrainStorm Cell Reports $2.7M Loss, Plans Phase 3b ALS Trial Despite Low Cash | BCLI Stock News - StockTitan
Pluri: Fiscal Q1 Earnings Snapshot - San Francisco Chronicle
Pluri (PLUR) to Present at Q4 Virtual Investor Summit: Biotech Showcase for Growth | PLUR Stock News - StockTitan
Pluri (PLUR) Announces Key Collaboration, Driving Stock Upward - Stocks Telegraph
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - PR Newswire
BrainStorm Teams with Pluri for Key NurOwn ALS Trial Manufacturing Partnership | PLUR Stock News - StockTitan
Pluri And Bar-Ilan University Partner To Advance MAIT Cell Therapy For Solid Tumors - Contract Pharma
Pluri Flat on Funding From Innovation Authority - Baystreet.ca
Pluri Collaborates with Bar-Ilan University to Advance - GlobeNewswire
Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority - StockTitan
Cell And Gene Therapy Contract Development And Manufacturing - openPR
Renaissance Technologies LLC Decreases Position in Pluri Inc. (NASDAQ:PLUR) - Defense World
(PLUR) Technical Pivots with Risk Controls - Stock Traders Daily
Plurilock (PLUR.V) lands $19 million deal, largest in their history - Equity.Guru
Pluri Inc. regains compliance with Nasdaq listing rules - Investing.com India
Pluri Inc. regains compliance with Nasdaq listing rules By Investing.com - Investing.com UK
Pluri Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com
TomTom (OTCMKTS:TMOAF) Short Interest Down 34.8% in September - Defense World
(PLUR) Proactive Strategies - Stock Traders Daily
The Plurilock (PLUR.V) rip is over: But is that the end of the play? - Equity.Guru
Plurilock’s Behavioral Biometrics: Next-Gen Cybersecurity with Scott Meyers - The Deep Dive
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing - Yahoo Finance
Plurilock Security joins forces with cloud platform for data protection - Mugglehead
Cell Therapy Manufacturing Market Size Projected to Reach - GlobeNewswire
Ever After Foods receives $10 million investment - Food Business News
Former CrowdStrike Director Reveals Plurilock’s Potential - The Deep Dive
Stem Cell Therapy Market Set to Skyrocket to $48.89 Billion by 2033, Fueled by 13.2% CAGR - BioSpace
Pluri Unveils Proprietary 3D Cell Expansion Technology - Contract Pharma
Cyber Warfare: Ex-CIA Officer Warns of New Global Conflict, With Bryan Cunningham of Plurilock Security - The Deep Dive
Pluri (NASDAQ:PLUR) versus Tarsus Pharmaceuticals (NASDAQ:TARS) Critical Review - American Banking and Market News
(PLUR) Trading Advice - Stock Traders Daily
Critical Survey: Tevogen Bio (NASDAQ:TVGN) versus Pluri (NASDAQ:PLUR) - Defense World
Spanish seafood processors slam plant-based seafood labeling practices; Steakholder Foods signs MoU with Sherry Herring - SeafoodSource
Spanish seafood processors slam plant-based seafood labeling practices; Tender Food products now in Clover locations - SeafoodSource
Pluri Inc. faces potential Nasdaq delisting over equity shortfall - Investing.com
Pluri Inc. faces potential Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
400% Stock Surge: What’s Next for Plurilock Security? | Ali Hakimzadeh - The Deep Dive
Pluri enters deal to manufacture Kadimastem’s AstroRx for ALS - ALS News Today
Pluri signs tech transfer, manufacturing agreement with Kadimastem - TipRanks
Pluri’s CDMO To Manufacture Kadimastem’s Cell Therapy Candidates - Contract Pharma
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates - Morningstar
(PLUR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Joe Sexton: Enhancing Plurilock’s Vision with Decades of Experience - The Deep Dive
Contrasting Pluri (NASDAQ:PLUR) & Relay Therapeutics (NASDAQ:RLAY) - American Banking and Market News
Plurilock Appoints Palantir Senior Advisor To Company’s Industry Advisory Council - The Deep Dive
Critical Comparison: Pluri (NASDAQ:PLUR) & Relay Therapeutics (NASDAQ:RLAY) - Defense World
Pluri (NASDAQ:PLUR) Trading 0.3% Higher - Defense World
Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs - Business Wire
Pluri Inc partners to boost global vegetable supply - Investing.com India
Pluri Inc partners to boost global vegetable supply By Investing.com - Investing.com Canada
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):